Pulse Biosciences develops Nano-pulse Stimulation (NPS) technology—nanosecond-duration electrical pulses that selectively ablate targeted cells without thermal damage—through its programmable nPulse System platform. The company's commercial and development pipeline spans soft tissue ablation (percutaneous electrode system for benign thyroid nodules and other indications) and cardiac applications (surgical clamp and catheter-based systems for atrial fibrillation treatment). Pulse targets cardiac surgeons, electrophysiologists, and surgical teams, competing in the large atrial fibrillation ablation market where its nonthermal technology claims advantages over incumbent radiofrequency, cryoablation, and microwave approaches in reducing thermal damage, scarring, and collateral injury while preserving safety margins near critical structures.